Page 35 - 《中国药房》2025年1期
P. 35

ERS是细胞应对各种压力的保护性反应。PERK作                       [ 7 ]  张秋林,林慧婷,周格,等. 链脲佐菌素腹腔注射制作大
          为 ERS 的关键传感器,在维持细胞稳态中发挥重要作                              鼠2型糖尿病模型的方式与剂量研究[J]. 按摩与康复医
          用。然而,PERK 的长期或过度激活会导致细胞功能紊                              学,2023,14(2):77-80.
                                               [15]
          乱,并与多种代谢性疾病相关,包括 T2DM 。FOXO1                            ZHANG Q L,LIN H T,ZHOU G,et al. The mode and
          作为关键转录因子之一,在T2DM的发生发展中扮演着                               dosage of streptozotocin intraperitoneal injection in estab‐
                                                                  lishment of type 2 diabetes rat model[J]. Chin Manip Re‐
          重要角色。具体而言,FOXO1 可通过抑制胰岛素信号
                                                                  habil Med,2023,14(2):77-80.
          传导及葡萄糖摄取、促进糖异生及脂质合成等机制,导
                                                             [ 8 ]  姜立娟 . 经典名方玉液汤通过 PI3K/AKT 信号途径改善
          致糖脂代谢紊乱,引发 IR,增加 T2DM 及其并发症的发
                                                                  2 型糖尿病胰岛素抵抗的作用及机制研究[D]. 长春:长
                [16]
          生风险 。当细胞发生氧化应激时,PERK被激活,进而
                                                                  春中医药大学,2021.
          使FOXO1磷酸化,增强其转录活性。激活的FOXO1一                             JIANG L J. Study on the effect and mechanism of Yuye
          方面可以诱导抗氧化酶的表达,发挥保护作用;另一方                                decoction on insulin resistance of type 2 diabetes mellitus
          面,过度激活FOXO1会加剧氧化应激和炎症反应,进一                              through  PI3K/AKT  signaling  pathway[D]. Changchun:
                                               [17]
          步损害胰岛β细胞功能,促进IR的发生发展 。本研究                               Changchun University of Chinese Medicine,2021.
          结果显示,经清血消脂降糖方干预后,T2DM 大鼠肝脏                         [ 9 ]  李杲. 脾胃论[M]. 北京:中国中医药出版社,2019:1.
          组织中 PERK、FOXO1 蛋白磷酸化水平降低,表明清血                           LI  G.  Treatise  on  the  spleen  and  stomach[M].  Beijing:
          消脂降糖方可能通过抑制 PERK/FOXO1 信号通路调控                           China  Publishing  House  of  Traditional  Chinese  Medi‐
          T2DM大鼠炎症反应及氧化应激水平,改善IR。                                 cine,2019:1.
              综上,清血消脂降糖方可调节 T2DM 大鼠糖脂代                       [10]  BO T,GAO L,YAO Z,et al. Hepatic selective insulin re‐
                                                                  sistance at the intersection of insulin signaling and meta‐
          谢、氧化应激和炎症水平,同时提高胰岛素敏感性,缓解
          肝脏损伤,从而改善 IR,其作用机制可能与抑制 PERK/                           bolic dysfunction-associated steatotic liver disease[J].Cell
                                                                  Metab,2024,36(5):947-968.
          FOXO1信号通路有关。本研究为清血消脂降糖方防治
                                                             [11]  GAO D N,JIAO J,WANG Z P,et al. The roles of cell-
          T2DM提供了实验依据,后续本课题组将深入研究其涉
                                                                  cell and organ-organ crosstalk in the type 2 diabetes melli‐
          及的分子机制。
                                                                  tus  associated  inflammatory  microenvironment[J].  Cyto‐
          参考文献                                                    kine Growth Factor Rev,2022,66:15-25.
          [ 1 ]  EFENDIĆ  S,LUFT  R,WAJNGOT  A.  Aspects  of  the   [12]  SCHIATTARELLA A,LOMBARDO M,MORLANDO M,
              pathogenesis  of  type  2  diabetes[J].  Endocr  Rev,1984,5  et al. The impact of a plant-based diet on gestational diabe‐
              (3):395-410.                                        tes:a review[J]. Antioxidants(Basel),2021,10(4):557.
          [ 2 ]  中华医学会糖尿病学分会.胰岛素抵抗相关临床问题专                    [13]  NIE X,ZHAO Z,ZHANG X,et al. Endophytes alleviate
              家共识:2022 版[J]. 中华糖尿病杂志,2022,14(12):                 drought-derived oxidative damage in Achnatherum inebrians
              1368-1379.                                          plants through increasing antioxidants and regulating host
              Chinese Diabetes Society.Expert consensus on insulin re‐  stress responses[J].Microb Ecol,2024,87(1):73.
              sistance:2022 edition [J]. Chin J Diabetes Mellit,2022,14  [14]  HSIEH P S,HO H H,TSAO S P,et al. Multi-strain pro-
              (12):1368-1379.                                     biotic supplement attenuates streptozotocin-induced type-
          [ 3 ]  YARIBEYGI H,FARROKHI F R,BUTLER A E,et al. In‐   2 diabetes by reducing inflammation and β-cell death in
              sulin  resistance:review  of  the  underlying  molecular   rats[J]. PLoS One,2021,16(6):e0251646.
              mechanisms[J]. J Cell Physiol,2019,234(6):8152-8161.  [15]  SHARMA R B,LANDA-GALVÁN H V,ALONSO L C.
          [ 4 ]  宋林阳,胡依萌,徐焱成,等. 胰岛素抵抗的再认识[J]. 中                   Living  dangerously:protective  and  harmful  ER  stress
              华糖尿病杂志,2022,14(12):1341-1347.                       responses in pancreatic β-cells[J]. Diabetes,2021,70(11):
              SONG L Y,HU Y M,XU Y C,et al. Re-conceptualization   2431-2443.
              of insulin resistance[J]. Chin J Diabetes Mellit,2022,14  [16]  ZHANG T ,DONG H H .FoxO1:a conductor of insulin
              (12):1341-1347.                                     signaling  to  glucose  and  lipid  metabolism[M].  Switzer‐
          [ 5 ]  HOTAMISLIGIL G S. Endoplasmic reticulum stress and   land:Springer International Publishing,2016:79-99.
              the  inflammatory  basis  of  metabolic  disease[J].  Cell,  [17]  CHEN  S  F,HENDERSON A,PETRIELLO  M  C,et  al.
              2010,140(6):900-917.                                Trimethylamine N-oxide binds and activates PERK to pro‐
          [ 6 ]  DU H X,MA Y P,WANG X Q,et al. Advanced glycation   mote metabolic dysfunction[J]. Cell Metab,2019,30(6):
              end  products  induce  skeletal  muscle  atrophy  and  insulin   1141-1151.e5.
              resistance via activating ROS-mediated ER stress PERK/        (收稿日期:2024-07-18  修回日期:2024-12-09)
              FOXO1  signaling[J].  Am  J  Physiol  Endocrinol  Metab,                            (编辑:林 静)
              2023,324(3):1341-1347.



          中国药房  2025年第36卷第1期                                                  China Pharmacy  2025 Vol. 36  No. 1    · 29 ·
   30   31   32   33   34   35   36   37   38   39   40